BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cormier J, Thomas K, Chari R, Pinson C. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006;10:761-80. [DOI: 10.1016/j.gassur.2005.10.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Shin D, Kim TH, Park SY, Kwak J, Moon SH, Yoon M, Lee SB, Park S, Shin KH, Kim DY, Cho KH, Park J, Kim C. Influence of Lipiodol Agent on Proton Beam Range in Radiotherapy Planning Using Computed Tomography for Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2008;72:687-94. [DOI: 10.1016/j.ijrobp.2008.01.059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
2 Hsieh M, Lin Z, Chen S, Chuang W. Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma. The Kaohsiung Journal of Medical Sciences 2011;27:431-6. [DOI: 10.1016/j.kjms.2011.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Kondo K, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J. Hepatic resection is justified for elderly patients with hepatocellular carcinoma. World J Surg. 2008;32:2223-2229. [PMID: 18642042 DOI: 10.1007/s00268-008-9688-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
4 Lee NPY, Leung K, Cheung N, Lam BY, Xu MZ, Sham PC, Lau GK, Poon RTP, Fan ST, Luk JM. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics 2008;8:2136-49. [DOI: 10.1002/pmic.200700590] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
5 Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomark Med 2007;1:273-84. [PMID: 20477402 DOI: 10.2217/17520363.1.2.273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
6 Allard MA, Sa Cunha A, Ruiz A, Vibert E, Sebagh M, Castaing D, Adam R. The postresection alpha-fetoprotein in cirrhotic patients with hepatocellular carcinoma. An independent predictor of outcome. J Gastrointest Surg. 2014;18:701-708. [PMID: 24402605 DOI: 10.1007/s11605-013-2433-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu M, Dong WG. Progress in non-surgical treatment of primary hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(12): 1224-1228 [DOI: 10.11569/wcjd.v17.i12.1224] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
8 Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L, Corvera CU. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford). 2008;10:405-411. [PMID: 19088925 DOI: 10.1080/13651820802356572] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
9 Danno K, Nakamura T, Okoso N, Nakamura N, Iguchi K, Iwadate Y, Kenmotsu T, Ikegawa M, Uemoto S, Yoshikawa K. Cracking pattern of tissue slices induced by external extension provides useful diagnostic information. Sci Rep 2018;8:12167. [PMID: 30111854 DOI: 10.1038/s41598-018-30662-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014; 20(44): 16630-16638 [PMID: 25469032 DOI: 10.3748/wjg.v20.i44.16630] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
11 Guan Y, He Q. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2011;12:303-13. [DOI: 10.1517/14656566.2011.546346] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
12 Yu DS, Chang H, Sommer CM, Qu WL, Xu WJ, Yang RJ, Zhao P. Efficacy and safety of percutaneous microwave coagulation therapy followed by 125I seed brachytherapy for VX2 hepatic tumors in a rabbit model. Exp Ther Med 2013;6:159-63. [PMID: 23935738 DOI: 10.3892/etm.2013.1088] [Reference Citation Analysis]
13 Sharifian M, Baharvand P, Moayyedkazemi A. Liver Cancer: New Insights into Surgical and Nonsurgical Treatments. CCTR 2021;17:197-206. [DOI: 10.2174/1573394717666210219104201] [Reference Citation Analysis]
14 Khan N, Bammidi S, Chattopadhyay S, Jayandharan GR. Combination Suicide Gene Delivery with an Adeno-Associated Virus Vector Encoding Inducible Caspase-9 and a Chemical Inducer of Dimerization Is Effective in a Xenotransplantation Model of Hepatocellular Carcinoma. Bioconjug Chem 2019;30:1754-62. [PMID: 31181889 DOI: 10.1021/acs.bioconjchem.9b00291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Coelho G, Vasconcelos K, Vasconcelos J, Barros M, Costa P, Borges G, Júnior J, Brasil I, Filho D, Viana C, Rocha T, Mesquita D, Garcia J. Orthotopic Liver Transplantation for Hepatocellular Carcinoma: One Center's Experience in the Northeast of Brazil. Transplantation Proceedings 2009;41:1740-2. [DOI: 10.1016/j.transproceed.2009.01.104] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
16 Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587-1596. [PMID: 19357924 DOI: 10.1245/s10434-009-0454-0] [Cited by in Crossref: 134] [Cited by in F6Publishing: 125] [Article Influence: 10.3] [Reference Citation Analysis]
17 Tong A, Zhang H, Li Z, Gou L, Wang Z, Wei H, Tang M, Liang S, Chen L, Huang C, Wei Y. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol 2008;61:791-802. [DOI: 10.1007/s00280-007-0536-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
18 Ong KW, Joseph B, Gyomber DV, Bolton DM, Lawrentschuk N. Nephrectomy for a renal metastasis of undiagnosed hepatocellular carcinoma arising from an orthotopic liver transplant undertaken for cryptogenic cirrhosis. Korean J Urol 2013;54:715-7. [PMID: 24175048 DOI: 10.4111/kju.2013.54.10.715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
19 Cunningham SC, Choti MA, Bellavance EC, Pawlik TM. Palliation of hepatic tumors. Surgical Oncology 2007;16:277-91. [DOI: 10.1016/j.suronc.2007.08.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
20 Rubio E, González J, Jimenéz M, Lucena JL, Gimenez L, Martinez Arrieta F, Cuervas-Mons V, Turrión VS. Right adrenal metastases of hepatocarcinoma after liver transplantation: case report and literature review. Transplant Proc 2009;41:1067-9. [PMID: 19376429 DOI: 10.1016/j.transproceed.2009.02.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
21 Liang XD, Dai YC, Li ZY, Gan MF, Zhang SR, Yin-Pan, Lu HS, Cao XQ, Zheng BJ, Bao LF, Wang DD, Zhang LM, Ma SL. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma. PLoS One 2014;9:e97739. [PMID: 24905462 DOI: 10.1371/journal.pone.0097739] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
22 Du SS, Zeng ZC, Tang ZY, Zhang ZY, Shi LS, Wu Z, Qiang M, Liu ZS. Regenerative capacity of normal and irradiated liver following partial hepatectomy in rats. Int J Radiat Biol 2009;85:1114-25. [PMID: 19995237 DOI: 10.3109/09553000903242115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 Nart D, Yaman B, Yilmaz F, Zeytunlu M, Karasu Z, Kiliç M. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2010;16:621-630. [PMID: 20440771 DOI: 10.1002/lt.22028] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
24 Wang MH, Ji Y, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Bi AH, Tan YS. Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. Int J Radiat Oncol Biol Phys 2010;76:467-76. [PMID: 19406586 DOI: 10.1016/j.ijrobp.2009.01.057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
25 Lin CI, Lin ZY, Hsieh MY, Huang CF, Chen SH, Chuang WL. Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma. Kaohsiung J Med Sci. 2011;27:554-559. [PMID: 22208538 DOI: 10.1016/j.kjms.2011.06.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
26 Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer. 2016;8:37-55. [PMID: 27398029 DOI: 10.4137/bic.s34413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
27 Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008;62:1271-1278. [PMID: 18284443 DOI: 10.1111/j.1742-1241.2007.01694.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 7.0] [Reference Citation Analysis]
28 Callegari E, Elamin BK, D’Abundo L, Falzoni S, Donvito G, Moshiri F, Milazzo M, Altavilla G, Giacomelli L, Fornari F. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One. 2013;8:e73964. [PMID: 24069256 DOI: 10.1371/journal.pone.0073964] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
29 Hennig M, Yip-Schneider MT, Wentz S, Wu H, Hekmatyar SK, Klein P, Bansal N, Schmidt CM. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology 2010;51:1218-25. [PMID: 20112426 DOI: 10.1002/hep.23470] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
30 Del Pozo AC, López P. Management of hepatocellular carcinoma. Clin Liver Dis. 2007;11:305-321. [PMID: 17606209 DOI: 10.1016/j.cld.2007.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
31 Tang QH, Li AJ, Yang GM, Lai EC, Zhou WP, Jiang ZH, Lau WY, Wu MC. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg. 2013;37:1362-1370. [PMID: 23456227 DOI: 10.1007/s00268-013-1969-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
32 Iida T, Shiba H, Misawa T, Ohashi T, Eto Y, Yanaga K. Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Cancer Science 2008;99:2097-103. [DOI: 10.1111/j.1349-7006.2008.00953.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
33 Xie X, Dendukuri N, McGregor M. Percutaneous radiofrequency ablation for the treatment of early stage hepatocellular carcinoma: a health technology assessment. Int J Technol Assess Health Care. 2010;26:390-397. [PMID: 20923590 DOI: 10.1017/S0266462310001029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Jiang LH, Hao YL, Zhu JW. Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2019;43:282-91. [PMID: 30385249 DOI: 10.1016/j.clinre.2018.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Karakayali H, Sevmis S, Moray G, Yilmaz U, Ozcay F, Savas N, Arslan G, Haberal M. Liver Transplantation in Patients With Hepatocellular Carcinoma: One Center’s Experience. Transplantation Proceedings 2008;40:213-8. [DOI: 10.1016/j.transproceed.2007.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 Grosfeld JL, Otte J. Liver Tumors in Children. In: Carachi R, Grosfeld JL, Azmy AF, editors. The Surgery of Childhood Tumors. Berlin: Springer Berlin Heidelberg; 2008. pp. 227-60. [DOI: 10.1007/978-3-540-29734-5_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Park UJ, Kim YH, Kang KJ, Lim TJ. [Risk factors for early recurrence after surgical resection for hepatocellular carcinoma]. Korean J Hepatol. 2008;14:371-380. [PMID: 18815460 DOI: 10.3350/kjhep.2008.14.3.371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
38 Duller D Jr, Stiegler P, Schweiger M, Kahn J, Kniepeiss D, Jakoby E, Tscheliessnigg K, Iberer F. Sensitive serum parameters for hepatocellular carcinoma recurrence monitoring after liver transplantation: a case report. Transplant Proc 2007;39:3281-3. [PMID: 18089371 DOI: 10.1016/j.transproceed.2007.04.030] [Reference Citation Analysis]
39 Saralidze K, Knetsch ML, van Berkel RG, Mostert C, Koole LH. Radiopaque microspheres for improved transarterial chemical embolization (TACE). Journal of Controlled Release 2011;152:e74-5. [DOI: 10.1016/j.jconrel.2011.08.132] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
40 Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, Kawanaka K, Beppu T, Sugiyama S, Sakamoto T, Yamashita Y, Oya N. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol. 2007;84:266-271. [PMID: 17716760 DOI: 10.1016/j.radonc.2007.07.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 5.3] [Reference Citation Analysis]
41 Cressman ENK, Tseng H, Talaie R, Henderson BM. A new heat source for thermochemical ablation based on redox chemistry: Initial studies using permanganate. International Journal of Hyperthermia 2010;26:327-37. [DOI: 10.3109/02656731003614516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
42 Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, Suga T, Kawashima H, Togashi K, Seo S, Kitamura K, Takada Y, Kamimoto S. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010;37:468-82. [DOI: 10.1007/s00259-009-1284-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
43 Lin JC, Shih YL, Chien PJ, Liu CL, Lee JJ, Liu TP, Ko WC, Shih CM. Increased percentage of B cells in patients with more advanced hepatocellular carcinoma. Hum Immunol. 2010;71:58-62. [PMID: 19819282 DOI: 10.1016/j.humimm.2009.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
44 Yu J. Targeting chemokines as a therapeutic option for hepatocellular carcinoma: A reality or just a fantasy?: Editorial. Journal of Gastroenterology and Hepatology 2007;22:611-2. [DOI: 10.1111/j.1440-1746.2007.04970.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Yao E, Chen J, Zhao X, Zheng Y, Wu X, Han F, Huang H, Liang P, Liu J, Wu F, Lin L. Efficacy of Stereotactic Body Radiotherapy for Recurrent or Residual Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. Biomed Res Int 2018;2018:5481909. [PMID: 29687004 DOI: 10.1155/2018/5481909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Palmieri VO, Grattagliano I, Minerva F, Pollice S, Palasciano G, Portincasa P. Liver Function as Assessed by Breath Tests in Patients With Hepatocellular Carcinoma. Journal of Surgical Research 2009;157:199-207. [DOI: 10.1016/j.jss.2008.09.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
47 Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31:461-76. [PMID: 19925500 DOI: 10.1111/j.1365-2036.2009.04200.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 122] [Article Influence: 9.9] [Reference Citation Analysis]
48 Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther 2008;25:787-94. [PMID: 18670743 DOI: 10.1007/s12325-008-0079-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
49 Guimaraes M, Uflacker R. Locoregional therapy for hepatocellular carcinoma. Clin Liver Dis 2011;15:395-421, vii-x. [PMID: 21689621 DOI: 10.1016/j.cld.2011.03.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
50 Kalva SP, Pectasides M, Liu R, Rachamreddy N, Surakanti S, Yeddula K, Ganguli S, Wicky S, Blaszkowsky LS, Zhu AX. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37:381-387. [PMID: 23754191 DOI: 10.1007/s00270-013-0654-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
51 Siveen KS, Nguyen AH, Lee JH, Li F, Singh SS, Kumar AP, Low G, Jha S, Tergaonkar V, Ahn KS, Sethi G. Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells. Br J Cancer 2014;111:1327-37. [PMID: 25101566 DOI: 10.1038/bjc.2014.422] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
52 Zhong NB, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: A clinical study. Mol Clin Oncol 2014;2:839-44. [PMID: 25054055 DOI: 10.3892/mco.2014.304] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
53 Yu Z, Liu W, Fan L, Shao J, Huang Y, Si X. The efficacy and safety of percutaneous microwave coagulation by a new microwave delivery system in large hepatocellular carcinomas: four case studies. Int J Hyperthermia. 2009;25:392-398. [PMID: 19551547 DOI: 10.1080/02656730902976815] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
54 Wang H, Gong G, Wang H, Li D, Yin Y, Lu J. Performance evaluations of demons and free form deformation algorithms for the liver region. Technol Cancer Res Treat 2014;13:101-8. [PMID: 23919395 DOI: 10.7785/tcrt.2012.500369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Zhong G, Qi J, Huo S, Xue H, Xu Z, Li J, Zhou Y, Wu M, Li L. Transarterial oily chemoembolization with lidamycin shows potent therapeutic efficacy in VX2 rabbit liver tumor. Onco Targets Ther 2015;8:3079-86. [PMID: 26543376 DOI: 10.2147/OTT.S89497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
56 Zhang M, Zhang C, Zhang L, Yang Q, Zhou S, Wen Q, Wang J. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer 2015;15:531. [PMID: 26194347 DOI: 10.1186/s12885-015-1541-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 10.6] [Reference Citation Analysis]